Inhalerx Ltd (IRX) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.044x

Based on the latest financial reports, Inhalerx Ltd (IRX) has a cash flow conversion efficiency ratio of -0.044x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$38.91K ≈ $27.53K USD) by net assets (AU$-877.11K ≈ $-620.61K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Inhalerx Ltd (IRX) net asset quality to measure how much of total assets are equity-financed.

Inhalerx Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Inhalerx Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Inhalerx Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Inhalerx Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Inhalerx Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Merino & Co. Ltd AU:MNC	-0.297x
Henderson International Income Trust PLC LSE:HINT	0.024x
Krida Jaringan Nusantara Tbk PT JK:KJEN	0.001x
Capitan Investment Ltd V:CAI	0.042x
ASIA Capital Group Public Company Limited BK:ACAP	0.032x
TAIZHOU WATER GRP. H YC 1 F:GX5	N/A
Sulliden Minerals SA TO:SMC	0.090x
Wide Open Agriculture Ltd AU:WOA	-0.429x

Annual Cash Flow Conversion Efficiency for Inhalerx Ltd (2016–2024)

The table below shows the annual cash flow conversion efficiency of Inhalerx Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Inhalerx Ltd stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	AU$-63.97K ≈ $-45.26K	AU$-368.77K ≈ $-260.93K	5.765x	+295.55%
2023-12-31	AU$665.47K ≈ $470.86K	AU$-1.96 Million ≈ $-1.39 Million	-2.948x	-203.82%
2022-12-31	AU$1.90 Million ≈ $1.35 Million	AU$-1.85 Million ≈ $-1.31 Million	-0.970x	-126.23%
2021-12-31	AU$2.68 Million ≈ $1.89 Million	AU$-1.15 Million ≈ $-812.69K	-0.429x	+47.70%
2020-12-31	AU$1.32 Million ≈ $936.76K	AU$-1.09 Million ≈ $-768.25K	-0.820x	+85.05%
2019-12-31	AU$340.08K ≈ $240.63K	AU$-1.87 Million ≈ $-1.32 Million	-5.487x	-613.06%
2018-12-31	AU$2.68 Million ≈ $1.90 Million	AU$-2.06 Million ≈ $-1.46 Million	-0.770x	-35.45%
2017-12-31	AU$4.51 Million ≈ $3.19 Million	AU$-2.56 Million ≈ $-1.81 Million	-0.568x	-1717.88%
2016-12-31	AU$7.33 Million ≈ $5.19 Million	AU$-229.03K ≈ $-162.05K	-0.031x	--

About Inhalerx Ltd

AU:IRX Australia Biotechnology

Market Cap

$4.18 Million

AU$5.91 Million AUD

Market Cap Rank

#28890 Global

#1568 in Australia

Share Price

AU$0.02

Change (1 day)

+4.35%

52-Week Range

AU$0.02 - AU$0.04

All Time High

AU$0.39